Cardiology

MD IQ

News

Empagliflozin gets HFrEF approval from FDA

The SGLT2 inhibitor empagliflozin (Jardiance) becomes the second agent from this class to get a heart failure indication regardless of diabetes...

Clinical

Use of point-of-care ultrasound (POCUS) for heart failure

Hospitalist use of POCUS may include guiding procedures, aiding in diagnosis, and assessing effectiveness of treatment.

Pages